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PathogenesisHendra virus (HeV) and Nipah virus (NiV) are recently-emerged, closely related and highly pathogenic
paramyxoviruses. We have analysed here the pathogenesis of the acute HeV infection using the new animal
model, golden hamster (Mesocricetus auratus), which is highly susceptible to HeV infection. HeV-speciﬁc RNA
and viral antigens were found in multiple organs and virus was isolated from different tissues. Dual
pathogenic mechanism was observed: parenchymal infection in various organs, including the brain, with
vasculitis and multinucleated syncytia in many blood vessels. Furthermore, monoclonal antibodies speciﬁc
for the NiV fusion protein neutralized HeV in vitro and efﬁciently protected hamsters from HeV if given
before infection. These results reveal the similarities between HeV and NiV pathogenesis, particularly in
affecting both respiratory and neuronal system. They demonstrate that hamster presents a convenient novel
animal model to study HeV infection, opening new perspectives to evaluate vaccine and therapeutic
approaches against this emergent infectious disease.
© 2009 Elsevier Inc. All rights reserved.Introduction
Hendra virus (HeV) and Nipah virus (NiV) are closely related,
recently-emerged paramyxoviruses, belonging to the genus Henipa-
virus. Both viruses are capable of causing considerable morbidity and
mortality in a number of mammalian species, including humans. HeV
was identiﬁed as the causative agent of an outbreak of acute
respiratory disease in humans and thoroughbred horses in Brisbane,
Australia in 1994 (Murray et al., 1995). Since its ﬁrst appearance, HeV
has emerged several times and the last human infections occurred in
July 2008, resulting in the death of one veterinarian (Sun, 2008). NiV
infection was detected for the ﬁrst time in 1998 in Malaysia, where it
caused disease in pigs and humans (Chua et al., 2000). In both viruses
the natural host was found to be the fruit bat (Pteropus species). HeV
isolates from humans and fruit bats in Australia appear to be identical
(Halpin et al., 1999) and NiV isolates fromwithin the same outbreak in
Malaysia were found to be similar (Eaton et al., 2006). However, later
NiV isolates from different Asian countries (Cambodia, Thailand,
Bangladesh and India) have greater differences (Harcourt et al., 2005).y Garnier, 69365 Lyon, France.
.
ll rights reserved.The reported human death rates also varied from 40% in Malaysia to
75% in Bangladesh and India, and some outbreaks were associated
with human to human transmission (Gurley et al., 2007). Due to the
wide distribution of pteropus fruit bats in Australia, southeast Asia,
India and Africa (Eaton et al., 2006), there is a constant risk that
Henipavirus will cross the species barrier to infect new hosts and
cause another outbreak, therefore presenting a constant danger to
public health.
Little is known of the time course of Henipavirus infections. HeV
infection has induced three fatal human cases, from a total of 6
infections reported so far (O'Sullivan et al., 1997; Selvey et al., 1995;
Wong et al., in press). In the ﬁrst fatal case, the patient developed a
respiratory disease and pathological analysis showed gross lesions of
congestion, haemorrhage and oedema of lungs, associated with
alveolitis with syncytia (Selvey et al., 1995) as well as acute
encephalitis (Wong et al., in press). Another patient developed a
lethal relapsing encephalitis about 1 year after the primary infection,
characterized by leptomeningitis, necrosis and inﬂammation in
different parts of the brain parenchyma (O'Sullivan et al., 1997; Sun,
2008) and the last, most recent patient who succumbed to HeV
infection was not analysed so far (Sun, 2008).
Experimental studies have demonstrated that horses, guinea pigs
and cats are susceptible to HeV infection (Hooper et al., 2001;
Table 1
Detection of HeV RNA by RT-PCR in various organs of infected hamsters.
Days
after
infectiona
Tissueb
Serum Urine Brain Lung Kidney Heart Liver Spleen
1 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
3 0/2 1/2 1/2 2/2 1/2 1/2 2/2 1/2
4 1/1 2/2 2/2 2/2 1/2 2/2 2/2 2/2
5 2/2 0/1 2/2 2/2 2/2 2/2 2/2 2/2
a Intraperitoneal infection with 103 PFU of HeV.
b Number of positive animals/total number of analysed animals.
460 V. Guillaume et al. / Virology 387 (2009) 459–465Williamson et al., 2001). Similar to the human case, all equine cases of
HeV infection have been associated with a respiratory disease and
neurological signs, and vascular disease resulting in localised cerebral
infarction (Hooper et al., 2001). Guinea pigs infected with high doses
of HeV developed encephalitis (Williamson et al., 2001), while
infection in cats was characterized by signiﬁcant respiratory symp-
toms and occasional deaths (Hooper et al., 2001). However, a small
animal model of HeV infection, reproducing both respiratory and
neurological problems observed in humans would be invaluable for
laboratory studies.
In the present study we have demonstrated the high susceptibility
of golden hamster to HeV and spread of infection into different organs.
Our results suggested the implication of the both parenchymal cell
infection and vasculitis in HeV pathogenesis. Furthermore, a series of
monoclonal antibodies (MAbs) speciﬁc for NiV attachment (G) and
fusion (F) proteins (Guillaume et al., 2006) have been tested for their
capacity to cross-react with HeV in vitro and in vivo. We show here
that MAbs directed against the NiV-F glycoprotein that neutralized
both NiV and HeV in vitro, protected the hamster from a lethal HeV
infection. Taken together, these results demonstrate that HeV, similar
to NiV, affects both respiratory system and the brain and suggest that
the golden hamster is a suitable new animal model to study the
pathogenesis of HeV infection and to develop new immunotherapeu-
tic approaches to this emergent infectious disease.
Results
Virulence of HeV infection in hamsters
To analyse the sensitivity of hamsters to HeV infection, seven
week-old hamsters (6 per group) were inoculated i.p. with 10-fold
dilutions of HeV (1 to 105 PFU/animal). Animals infected with 103 PFU
or more died within 6 dpi. Two hamsters infected with 10 PFU died at
14 and 27 dpi, respectively (Fig. 1A). In each case, 24 h prior to death,
clinical symptoms included paralysis and trembling limbs which
rapidly evolved into prostration and breathing difﬁculties. Further-
more, numerous animals had blood in their nasal secretions, salivaFig. 1. Survival curves of hamsters infected HeV. (A) Hamsters (seven-week-old, six per
group) were inoculated i.p. with 10-fold dilutions of HeV. (B) Seven-week-old or
eleven-week-old hamsters (ﬁve per group) that were infected by 100 LD50 or 1000 LD50
of HeV. Animals were examined daily for the development of clinical symptoms.and urine in the ﬁnal stages. Viral RNA was detected by RT-PCR in all
these secretions (data not shown). Sera from animals which survived
infection 30 dpi or more and tested for the presence of anti-HeV
antibodies by ELISA were all negative. The LD50 of HeV infection in
hamsters was calculated to be 12 PFU.
In the experiment to investigate the possibility of HeV trans-
mission between animals by housing uninfected and infected
hamsters together in the same cage for 35 days, none of the uninfected
animals became ill or showed evidence of seroconversion.
We next analysed whether the age of the animal could inﬂuence
the virulence of HeV infection. Groups of 5 seven-week-old (80 g) or
eleven-week-old (110 g) hamsters were infected with either 100 or
1000 LD50 (Fig. 1B). All animals inoculated with 1000 LD50 died by
5 dpi or became very sick, and were euthanized. However, only half
the 11-week-old animals infected with 100 LD50s of HeV had died by
this time. The remainder died up to 12 dpi, and a single animal
survived, suggesting that sensitivity to HeV infection may decrease
with the increasing age of the animals.
Kinetics of HeV infection and spread in different organs studied by
RT-PCR
To analyse HeV spread into different organs, seven-week-old
hamsters were infected with 103 PFU of HeV and followed up for 5 dpi.
Each day a set of organs and tissues were taken (2 hamsters/day), RNA
was extracted and examined for the presence of viral transcripts. No
evidence of infection was detected up to 2 dpi (Table 1). However, by
3 dpi, HeV were detected in brain, lung, heart, liver and spleen, and by
4 dpi, infection had spread to all organs examined. The presence of
virus in the serum and urine was a late phenomenon. These results
suggest that HeV spreads to various organs, starting from the 3 dpi.
Time course of infection in different organs studied by histopathology
Tissues from HeV-infected animals were analysed for histopatho-
logical changes and the presence of viral antigens at different time
points after infection in a group of 10 hamsters infected with 103 PFU
(Table 2).
From 1 to 2 dpi, signiﬁcant speciﬁc microscopic features of HeV
infection or inﬂammation, were not seen (Fig. 2A), except for scattered
mild foci of inﬂammation in the lung and spleen at 2 dpi (Table 2). At
3 dpi onwards, the lungs showedmorewell-deﬁned nodular aggregates
of inﬂammatory cells in the parenchyma (Figs. 2B, C). However all the
other organs (brain, heart, kidney, liver and spleen) did not show
signiﬁcant inﬂammation. From 4 to 5 dpi hyalinized necrotic blood
vessels were observed in the lung, liver (Fig. 2O), kidney and spleen, but
not in the brain or aorta. Increasing numbers of endothelial syncytia
were also seen in the pulmonary vessels (Fig. 2D) but vascular syncytia
were not prominent in the other organs. A few necrotic plaques were
observed in the brain (Fig. 2G) and spleen.
At 2 dpi, focal, small amounts of viral antigens were noted in lung,
kidney and spleen. Signiﬁcantly larger amounts of viral antigens began
to appear from 3 to 5 dpi, in the lung, brain, kidney, liver, heart and
Table 2
Histological and immunohistochemistry (IHC) analysis of organs from HeV-infected.
Days
after
infectiona
Brain Lungs Kidney Heart Liver Spleen
Histol. lesionsb IHCb Histol. lesions IHC Histol. lesions IHC Histol. lesions IHC Histol. lesions IHC Histol. lesions IHC
1 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
2 0/2 0/2 1/2 1/2 0/2 1/2 0/2 0/2 0/2 0/2 2/2 1/2
3 0/2 2/2 2/2 2/2 0/2 2/2 0/2 1/1 0/2 2/2 0/2 1/2
4 1/1 1/1 1/1 1/1 2/2 2/2 0/2 2/2 1/1 1/1 2/2 2/2
5 2/2 2/2 2/2 2/2 2/2 2/2 0/2 2/2 2/2 2/2 1/2 1/2
a Intraperitoneal infection with 103 PFU of HeV.
b Number of positive animals/total number of analysed animals; the counts are qualitative: if there is a single pathological lesion, either histological (histol.) or by
immunohistochemistry (IHC), the organ is counted as positive.
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predominantly in inﬂammatory aggregates, alveolar walls and blood
vessels (Figs. 2E, F). In the brain large plaque-like neuronal/neuropil
IHC positivity could be found in the cerebellum and cerebral cortex
(Fig. 2H). Neuronal staining was the most prominent but viral
antigens could also be detected in the meningeal membrane, blood
vessel (Fig. 2I) and ependyma. In the kidney, viral antigens were
mainly conﬁned to glomeruli (Fig. 2J), tubules (Fig. 2K) and occasional
blood vessel (Fig. 2L). IHC staining in the heart and aorta involved the
endocardium and endothelium, respectively (Fig. 2M). In the liver,
staining was mainly in blood vessels and sinusoids (Figs. 2N). In the
spleen, lymphocytes, blood vessels, mesothelial cells were positive. The
histopathological lesions and immunhistochemistry ﬁndings in the
animals infected with high dose (105 PFU) HeV were similar to those
infected with 103 PFU but generally, the lesions appeared to be more
ﬂorid.
Isolation of infectious HeV from tissues of infected hamsters
To further analyse HeV replication and determine virus titers in
different organs, a wide range of tissues was tested for the presence of
infectious virus particles (Fig. 3). Although some infectious virus could
be isolated from lungs, kidneys and brain at 3 dpi in some animals
(data not shown), at 4 dpi a wide-spread viral replication is observed
in most of the tested organs, being highest in kidneys, with the
variation in the titer among individual animals. Interestingly, no virus
could be isolated from intestines and only low level was detected in
urinary bladder (Fig. 3).
Passive immunoprotection studies
Our previous studies using neutralizing MAbs speciﬁc for NiV-G or
-F glycoproteins showed that hamsters can be efﬁciently protected
against a lethal infection of NiV (Guillaume et al., 2006). In the present
study, we characterized additional MAbs for their properties to
neutralize NiV, cross-react with HeV in ELISA and in neutralization
assays, and to protect against HeV infection in vivo.
From 4 anti-NiV-G MAb tested in this study, only two of them
cross-react with HeV in ELISA (Table 3), suggesting that they do not all
recognize the same epitopes on NiV-G or/and they may have rather
different binding afﬁnity. However, none of the anti-NiV-G antibodies
neutralized HeV. In contrast to anti-NiV-G MAb, certain anti-NiV-F
MAbs (Nip GIP35, Nip GIP3, Nip GIP7 and Nip GIP21) neutralized HeV
as well, with almost the same efﬁciency as for NiV (Table 3). In order
to assess the potential prophylactic protection of the anti-NiV-F MAbs
against HeV infection in the hamster model, groups of six hamsters
were inoculated each with one of the 4 anti-NiV-F Mabs: Nip GIP35,
Nip GIP3, Nip GIP7 or Nip GIP21, 1 h prior to and 24 h after i.p
challenge with HeV (103 PFU). Animals were injected with the MAb
dose corresponding to the maximal concentration contained in the
each of available MAbs stocks. The hamsters were checked daily for up
to one month. The results show that passive administration of theseMAbs completely protected all hamsters from death, while control
hamsters that had not received MAbs died within seven days.
In order to test the efﬁciency of the passive protection by anti-NiV-F,
3 dilutions of the Nip GIP21 (3 μg, 30 μg, 300 μg) were inoculated into
hamsters 1 h before a lethal challenge with HeV. The hamsters were
then observed for 2 weeks. The results (Fig. 4) showed that 5 out of 6
hamsters receiving 300 μg of anti-NiV-F were completely protected,
while half of the animalswere protectedwith single dose 30 μg and32%
with 3 μg pf MAb, corresponding to 3, 0.3 and 0.03 mg/kg of the given
MAb respectively. In the control group of hamsters one survived the
challenge with HeV. This survival may be linked to the fact that these
hamsters had a higher weight than during previous experiments, being
potentially more resistant to infection. Taken together, these results
suggest that anti-NiV-FMAbs could be used in passive cross-protection
against HeV and demonstrate that the golden hamster is a suitable
animal model for these types of studies.
Discussion
Viruses have been constantly crossing the species barrier from
their natural hosts to infect other animals or humans. This
phenomenon is only brought to notice when the virus has a virulent
outcome in the accidental host. Thus, canine distemper virus
attenuated for domestic dogs is fatal in a number of wild animals
(Carpenter et al., 1976). Pathogenicity of HeV and NiV in various
animal hosts is rather different and often less severe than in humans
(Eaton et al., 2006). The key to understanding the pathogenic features
of viruses and the generation of therapeutics and vaccines is the
development of suitable animal models to study viral pathogenesis.
Although different animals have been shown to be susceptible to
HeV infection, a small convenient laboratory model for this emergent
infectious disease, adapted for manipulation in BSL-4 has been
lacking. We have therefore, characterized the golden hamster as a
new animal model of HeV infection. We showed that it closely
resembles the pathology observed in acute human HeV infections,
including both respiratory and brain pathology. The autopsy ﬁndings
from human cases of acute Hendra virus infection showed also the
vasculitis in different organs, including kidney glomeruli and heart in
addition to the brain and lungs. Moreover, the inﬂammation and viral
antigens were found in capillary walls and podocytes in kidneys
(O'Sullivan et al., 1997; Selvey et al., 1995; Wong et al., in press).
Furthermore, we have analysed the time course of HeV infection in
this model and demonstrated that HeV induces systemic infection in
hamsters with pathology similar to what has been seen previously in
NiV infection (Wong et al., 2003). The pathology in the HeV-infected
hamsters that consisted of endothelial infection and vasculitis is
believed to give rise to thrombosis and microinfarction. At the same
time, there was evidence of direct parenchymal cell infection, notably
in the central nervous system. Thus these ﬁndings conﬁrmed that in
HeV infection, like NiV, a dual pathogenetic mechanism of vasculitis-
induced microinfarction and direct parenchymal cell infection may be
responsible for the pathological changes and disease.
Fig. 2. Pathology of acute Hendra virus infection in the lung (A–F), brain (G–I), kidney (J–L), aorta (M) and liver (N–O). No inﬂammation in the lung (A) at 1 day postinfection (dpi)
but increasing degree of nodular lung inﬂammation (arrows) began to appear at 3 dpi (B) and 5 dpi (C). Multiple endothelial syncytia in pulmonary vessels were also observed (D,
arrows). Viral antigens (brown stains) were detected within nodular inﬂammatory cell aggregates (E, F) and in vascular endothelial lining (F, thin arrows) and syncytia (F, thick
arrow). In the brain parenchyma, discrete necrotic plaque (G), and viral antigens in cerebellar neurons (H) and meningeal blood vessels (I, arrows) were observed. In the kidney
glomerulus (J), tubules (K) and blood vessel walls (L, arrows), viral antigens were also detected. The aorta (M, arrows), and hepatic sinusoids (N) and endothelial syncytia (N, arrow)
were also positive for viral antigens. Hepatic arteries also showed evidence of transmural necrosis and vasculitis (O, arrow). A to D, G, O: Haematoxylin and eosin stains; E, F, H to N:
immunohistochemistry/DAB/haematoxylin. Magniﬁcation: A to C: ×4 objective; E, G, M: ×10 objective; D, F, H to L, N, O: ×40 objective.
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infection has also been observed in a feline model. Infection of cats
with NiV induces an acute febrile reaction followed by severerespiratory disease (Hooper et al., 2001). There was an apparent
lack of neurological signs, despite the demonstration of the NiV
genome in brain tissue (Mungall et al., 2006). However, while guinea
Fig. 3. HeV replication in tissues from infected hamsters. Four 7-week-old hamsters
were infected with 106 PFU of HeV and sacriﬁced 4 days later. Virus titer was
determined as described in Materials and methods.
Fig. 4. Passive protection against HeV in hamster using three concentrations of the MAb
anti-NiV-F Nip GIP21. Groups of 6 hamsters were inoculated i.p. with indicated
concentrations of MAb or PBS, 1 h prior to infection with 103 PFU of HeV and followed
daily for the development of clinical symptoms.
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son et al., 2001), different results were obtained with NiV: only
transient fever and weight loss in one study (Wong et al., 2003), in
contrast to 90% of mortality 4 and 8 days after infection, in the other
study (Torres-Velez et al., 2008). Finally, it has recently been shown
that HeV induces in humans the pathology similar to what has been
observed with NiV, including both acute and relapsing encephalitis, in
addition to the acute pulmonary syndrome andwide-spread vasculitis
(Wong et al., in press).
HeV was only found late in infection in sera from infected
hamsters, suggesting the absence of a viremia preceding the virus
spread to different organs and indicating a differentmode of the initial
propagation of infection. This is in accord with the observation made
with pigs experimentally infected with NiV, where after the initial
replication in the upper respiratory tract, the virus invades the central
nervous system directly via the cranial nerves and by crossing the
blood brain barrier (Weingartl et al., 2005). Concurrently with the
spread through the nervous and lymphoreticular systems, NiV also
replicated in the respiratory system including the lungs. Finally, in
contrast to NiV infection (Guillaume et al., 2004a; Guillaume et al.,
2006), HeV infection seems to be less virulent in older hamsters,
where a 10 times higher dose of virus was required to obtain 100%
mortality. Development of some age-related resistance factors,
speciﬁc for HeV and not NiV and present in more mature animals,
may be responsible for this difference seen between two viruses.
As both HeV and NiV use the same cellular receptor molecules,
ephrin-B2 and ephrin-B3 (Bonaparte et al., 2005; Negrete et al., 2007),Table 3
Speciﬁcity and neutralization capacity of anti-NiV MAbs used in passive protection against
MAb Speciﬁcity Isotype Detection by
ELISAa
HeV
Nip GIP 1.7 G IgG1 −
Nip 3B10 G IgG1 −
Nip 5G11 G IgG1 +
Nip 7D9 G IgG1 +
Nip GIP35 F IgG1 +
Nip GIP3 F IgG2a +
Nip GIP7 F IgG2a +
Nip GIP21 F IgG2a +
a Detection of HeV in the ELISA, by tested MAbs: reaction detected (+); not detected (−
b Neutralizing titers are expressed as the amount of IgG Mabs (in nanograms) required t
c Passive protection studies in hamsters (six animals per group) by anti-NiVMAbs injected
HeV infection (mean time of death: 6,8 days). nd: not determined.similar tissue targets of these two viruses are not surprising. High
conservation of ephrin-B2 and ephrin-B3 among different species
(human, horse, pig, cat, bat) and similar receptor function (Bossart
et al., 2008) is responsible for the broad species tropism of these two
viruses. Finally, the rather wide expression of these two receptors
among different cell types and tissues (Hafner et al., 2004), and its
overall expression on endothelial cells present in all organs, probably
allows virus spreading to the whole organism, although the way virus
propagates remains to be determined.
Currently, there are no vaccines available for preventing NiV or
HeV infection. As henipaviruses are BSL-4 agents, human efﬁciency
studies for testing potential therapeutic products are not easily
achievable, underlying the importance of the development of animal
models and their utilisation for testing different immunoprophylaxis
approaches. We have generated a series of MAbs speciﬁc for NiV-G
and NiV-F proteins (Guillaume et al., 2006) and have tested in this
study their immunoprophylaxis potential against HeV in the hamster
model. Interestingly, although cross-reaction was detected by ELISA
for both anti-NiV-F and NiV-G MAbs, only anti-NiV-F were able to
neutralize HeV, with a similar efﬁciency to NiV. In contrast to our
results, recently generated human MAb, developed using soluble
HeV-G to screen a human phage display library, showed high cross-
reactivity and neutralizing capacity against both HeV and NiV (Zhu
et al., 2008; Zhu et al., 2006). In addition, administration of the
soluble HeV-G into rabbits elicited a cross-neutralization Ab
response against both HeV and NiV infection (Bossart et al., 2005).
Our MAbs were generated in mice, using NiV-G in the nativeHeV.
In vitro
neutralization activityb
In vivo protection against
HeV infectionc
HeV NiV Quantity of given
MAb (mg/kg)
% of surviving
animals
NN 0.27 nd nd
NN 0.9 nd nd
NN 0.55 nd nd
NN 2.34 nd nd
14 14 2.5 100
40 20 6 100
34 34 2.7 100
425 107 4.2 100
).
o completely neutralize 25 PFU of HeV or NiV (IC90); NN: neutralization not observed.
1 h prior and 24 h after a lethal challenge of HeV. All 6 control animals succumbed to the
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the oligomeric state of the antigenused for immunization anddifferent
methods of generatingMAbs, as well as the higher homology between
HeV and NiV-F proteins (88.1%) than between G proteins (83.3%)
(Harcourt et al., 2000) could explain why we found cross-reactivity
only for our anti-F MAbs. These results suggest that anti-F MAbs have
potential as therapeutic agents for the treatment of diseases caused by
henipaviruses.
In summary, this study presents the characterization of a golden
hamster, which we show to be a suitable animal model as it is highly
susceptible to HeV infection and display pathological features similar
to the human infection. High mortality after infection makes this
model a valuable tool to test innovative therapeutic strategies against
HeV infection in BSL-4 conditions. Finally, MAbs, tested in this study,
which cross-react with both HeV and NiV, could be used in
prophylaxis and diagnosis as well as in further research studies in
the ﬁeld of these emergent viral infections.
Materials and methods
Viruses
HeV was obtained from Graham Lloyd at the exotic virus bank at
Porton Down, England. NiV isolated from the cerebrospinal ﬂuid of a
patient was received from Dr. K.B. Chua and Dr. S.K. Lam (University of
Malaya, Kuala Lumpur, Malaysia). HeV and NiV stocks were prepared
by infecting Vero-E6 cells as previously described (Guillaume et al.,
2004b), in the INSERM Jean Mérieux biosafety level 4 (BSL-4)
laboratory in Lyon, France.
Hamster infection experiments
Seven, eight or eleven-week-old golden hamsters (Mesocricetus
auratus; Janvier, France) 5–7 animals/group, were anaesthetized and
infected intraperitoneally (i.p.) with 0.4 ml of HeV, in the BSL-4
laboratory. Initial experiments were performed on seven-week-old
animals using 10-fold dilution of HeV to determine the susceptibility
of hamsters to HeV infection, and the dose needed to kill 50% of the
animals (LD50) was calculated using the Reed and Muench method
(Reed and Muench, 1938). Surviving animals were bled on 0, 6, 12, 19
and 27 days postinfection (dpi), and the sera were pooled for each
group and frozen at −80 °C until tested by ELISA. To investigate the
possibility of reinfection between animals housed within the same
cage, four uninfected hamsters were placed together with two
hamsters infected with 100 LD50. The uninfected animals were
checked daily up to 35 dpi. To study the pathology induced by HeV,
tissue specimens (brain, lung, heart, liver, spleen, kidney, urine and
blood) were collected daily over ﬁve dpi. Tissues were frozen at
−80 °C for reverse transcriptase PCR (RT-PCR) analysis for virus
isolation. For histopathological studies, tissues were ﬁxed in 10%
paraformaldehyde. All experimental protocols were approved by the
Regional ethical committee (CREEA).
RT-PCR
RNA was extracted from different organs as described (Guillaume
et al., 2006) and one step RT-PCR was conducted using a high-ﬁdelity
PCR enzyme blend (Roche Applied Science, Germany). HeV RNA was
analysed using a nucleoprotein speciﬁc primers He-NP143 (5′-
GATGGGAGTTGACTTTG-3′) and He-NP355 (5′-CAGCTTCTATGTCT-
GGGTCG-3′).
Virus isolation and titration
The titer of infectious HeV in tissues from infected hamsters was
determined by plaque titration onVero cells. A small fragment (30mg)of different tissues was mechanically crashed (Minibeadbeater,
Biospec, Bartlesville) twice for 30 s each in tubes containing sterile
glass beads and 0.5ml of DMEMand centrifuged at 3000 rpm for 5min
at 4 °C, and the supernatant was titrated on Vero cell monolayers as
described (Guillaume et al., 2004b).
Virus neutralization assays
NiV-speciﬁc MAbs (Guillaume et al., 2006) were assayed using
two-fold dilutions of MAb samples. Diluted ascitic ﬂuid samples were
incubated with HeV or NiV (25 PFU/well in 96-well microtiter plates)
for 60 min at 37 °C in Dulbecco's modiﬁed Eagle's medium
supplemented with 2% FCS. A total of 2.5×104 Vero cells were then
added to each well as indicator cells, and the 96-well microtiter plates
were incubated for 4–6 days at 37 °C. Neutralizing titers are expressed
as the amount of MAb IgG required to completely inhibit the
cytopathic effect (IC90).
ELISA
Microtiter plates (Dominic Dutscher)were coatedwith 100 μl/well
of HeV or NiV antigen, prepared as described previously (Guillaume
et al., 2004a) and incubated overnight at 4 °C. Wells were blocked for
30 min at 37 °C and the wells were washed with PBS containing 0.05%
Tween 20, between each step. The reaction was revealed with the
appropriate anti-mouse immunoglobulin G (IgG) -speciﬁc (Sigma-
Aldrich, France) conjugated to peroxidase for 30min at 37 °C, followed
by TMB (3,3′,5,5′ tetramethylbenzidine) liquid peroxidase substrate
system (Sigma-Aldrich, France) and stopped with sulphuric acid. The
optical density was read at 450 nm.
Immunohistochemistry (IHC)
Paraformaldehyde-ﬁxed tissues were trimmed and routinely
processed. Parafﬁn sections, 4microns thick, were placed on silianized
slides and deparafﬁnized by xylene and serial ethanol washes. Antigen
was retrieved by microwaving the sections in citrate buffer, pH 6.0 at
99 °C for 20 min. Endogenous peroxidase was blocked with 0.6%
H2O2 in methanol for 20 min. The IHC procedure was slightly
modiﬁed from a previous method (Wong et al., 2002) using anti-
HeV antibody (gift from Dr SR Zaki, USA), dilution 1:1000 to
1:2000, incubated for 1 h at RT. This was followed by incubation
with Dako REAL EnVision HRP rabbit/mouse (Dako Cytomation,
Denmark) followed by the substrate DAB according to the
manufacturer's protocol. The slides were counterstained with
haematoxylin and coverslipped.
Passive antibody transfer
The production of anti-NiV-F and anti-NiV-G has been described
previously (Guillaume et al., 2006z). To analyse the prophylactic
capacity of the anti-NiV-F MAbs against HeV infection (103 PFU),
groups of 6 hamsters (7-week-old) were injected i.p. with the
different amounts of MAbs either 1 h before infection or combined
1 h before and 1 day after infection. Animals were examined daily for
clinical signs of infection.
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